1. OSGIN1 promotes ferroptosis resistance by directly enhancing GCLM activity.
- Author
-
Jia Y, Zhang X, Cai Y, Yu H, Cao G, Dai E, Kang R, Tang D, Hu N, and Han L
- Subjects
- Humans, Cell Line, Tumor, Animals, NF-E2-Related Factor 2 metabolism, NF-E2-Related Factor 2 genetics, Oxidative Stress, Carcinoma, Pancreatic Ductal metabolism, Carcinoma, Pancreatic Ductal genetics, Carcinoma, Pancreatic Ductal pathology, Mice, Ferroptosis genetics, Pancreatic Neoplasms pathology, Pancreatic Neoplasms metabolism, Pancreatic Neoplasms genetics, Glutamate-Cysteine Ligase genetics, Glutamate-Cysteine Ligase metabolism
- Abstract
Oxidative stress induced growth inhibitor 1 (OSGIN1) is a tumor protein p53 (TP53)-target gene involved in the oxidative stress response and promotes apoptosis. Here, we present the first evidence that OSGIN1 functions conversely by inhibiting ferroptosis, a distinct form of oxidative cell death driven by excessive lipid peroxidation. OSGIN1 expression is upregulated by pharmacological ferroptosis inducers in an NFE2 like BZIP transcription factor 2 (NFE2L2)-dependent manner, rather than through the TP53 pathway, in human pancreatic ductal adenocarcinoma (PDAC) cells. Genetic depletion of OSGIN1 or NFE2L2 similarly promotes ferroptosis, while re-expression of OSGIN1 rescues ferroptosis resistance in NFE2L2-knockout cells, both in vitro and in animal models. Mechanistically, immunoprecipitation combined with mass spectrometry revealed that OSGIN1 interacts with glutamate-cysteine ligase modifier subunit (GCLM), enhancing glutathione production and thereby mitigating oxidative stress. Additionally, OSGIN1 expression shows a positive correlation with NFE2L2 expression in pancreatic tumors, which is linked to poorer prognosis in PDAC patients. Collectively, these findings establish a novel defense mechanism that regulates ferroptosis and may influence tumor suppression in PDAC., Competing Interests: Declaration of competing interest The authors declare that they have no competing interests., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF